As a young adult living with a chronic lung disease, I’ve heard horror stories of general physicians (GP) and specialists failing to listen to their patients. In the rare disease community, this is a common complaint by patients, and many of us wind up supporting one another when frustration boils…
A significant proportion of people with idiopathic pulmonary fibrosis (IPF) were found to have the sleep disorder restless legs syndrome (RLS), compared to a control group, according to new research. The data also showed that having RLS lowered sleep quality in IPF patients. The study, “Restless…
The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and access to healthcare, among other…
The Phase 2b GALACTIC-1 trial testing Galecto’s candidate GB0139 as an inhalation therapy for idiopathic pulmonary fibrosis (IPF) has recruited more than 150 patients to date, remaining on track despite the current COVID-19 pandemic, the company announced. The study (NCT03832946), underway across centers in the U.S.,…
Algernon Pharmaceuticals received the first ethics approval for its Phase 2 clinical trial in Australia evaluating its repurposed compound NP-120 (ifenprodil) for the treatment of idiopathic pulmonary fibrosis (IPF) and associated chronic cough. Royal Brisbane and Women’s Hospital‘s Human Research Ethics Committee has approved two sites — the Cairns…
Last weekend, my column turned 1! There were only a few weeks in the past year that I did not write a post for Pulmonary Fibrosis News. This means that I have had about 50 opportunities to share my family’s story with the world. I have tried to…
GB0139, Galecto’s lead compound to treat various fibrotic diseases of the lungs, has shown strong anti-fibrotic activity in a mouse model of idiopathic pulmonary fibrosis (IPF) and in IPF patients in a completed Phase 2a trial. A randomized, double-blind and placebo controlled Phase 2b trial (NCT03832946)…
Most of my friends and family members would say I am an open book about my chronic illness. After the initial shock wore off from being diagnosed with a life-threatening lung disease at 28, I decided to share my story through writing. Serena Lawrence, the late senior managing columns…
Loss of NEDD4-2 — a protein involved in the regulation of airway hydration and mucus clearance — leads to the onset and development of typical manifestations of idiopathic pulmonary fibrosis (IPF) in adult mice, a study has found. These findings, along with the establishment of a new animal…
Severe fatigue is common among people with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis, and is associated with worse shortness of breath, depression, catastrophizing, and quality of life, a new study suggests. The study, “Severe Fatigue is Highly Prevalent in Patients with IPF or…
Get regular updates to your inbox.
